Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Opioid Agonist Clear all
Completed Phase 2 Interventional Results available

Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)

NCT04772222
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Pain
Interventions
Dexmedetomidine Hydrochloride, Morphine Sulfate
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 24 Hours
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Murray, Utah • Ogden, Utah • Provo, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 4 Interventional Results available

Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis

NCT01195116
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Dexmedetomidine, Normal Saline
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

NCT00877799
View directory record Official record
Conditions
Acute Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Impact of Lofexidine on Stress, Craving and Opioid Use

NCT03718065
View directory record Official record
Conditions
Opioid-use Disorder, Opiate Dependence
Interventions
Lofexidine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

NCT04571619
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Pain, Opioid Dependence
Interventions
Pain Coping Skills Training (PCST), Buprenorphine
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
West Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

NCT01983306
View directory record Official record
Conditions
Constipation
Interventions
SP-333 1 mg, SP-333 3 mg, SP-333 6 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

A Study of Varenicline in the Treatment of Visceral Sensation

NCT06854406
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Varenicline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

NCT01789476
View directory record Official record
Conditions
Acute Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Not applicable Interventional Results available

Computer Based Treatment for Cognitive Behavioral Therapy and Cooperative Pain Education and Self-Management

NCT05204576
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
CBT4CBT COPES
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Bridgeport, Connecticut • Danbury, Connecticut • Waterbury, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 3 Interventional

Combining Behavioral Treatment With Agonist Maintenance - 1

NCT00000311
View directory record Official record
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine, methadone
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1999
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 27, 2026, 1:08 PM EDT
Suspended Phase 2 Interventional

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

NCT04912115
View directory record Official record
Conditions
Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
PharmaTher Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

NCT00993863
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, ADL5859 30 mg, ADL5859 100 mg, ADL5859 200 mg, ibuprofen 400 mg
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

NCT02475447
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 27, 2026, 1:08 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Oral MG001

NCT07204171
View directory record Official record
Conditions
Safety and Tolerability in Healthy Subjects
Interventions
mitragynine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Cannabis and Opioid Use Disorder

NCT05729932
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Inhaled vaporized cannabis, Intransal opioid
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Recruiting Not applicable Interventional

Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents

NCT06732596
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Embodied conversational agent (ECA), Technical support, Additional ECA messages, Additional incentives
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

NCT07800520
View directory record Official record
Conditions
Opioid Use Disorder, OAT
Interventions
[11C]OMAR
Drug
Lead sponsor
Yale University
Other
Eligibility
25 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Active, not recruiting Not applicable Interventional

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

NCT05733442
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Treatment as usual (TAU), CHaRRM-CN
Other
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tahlequah, Oklahoma • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

NCT01361568
View directory record Official record
Conditions
Postoperative Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Florence, Alabama • Mobile, Alabama • Montgomery, Alabama + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 27, 2026, 1:08 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Better Options for Chronic Cancer Pain

NCT06574009
View directory record Official record
Conditions
Chronic Pain, Cancer Survivor, Opioid Dependence
Interventions
Multimodal pain care, Medication optimization, Buprenorphine rotation, Opioid tapering
Behavioral · Drug · Device + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol in the Treatment of Opioid Use Disorder

NCT06206291
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Placebo, Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg
Drug
Lead sponsor
Yasmin Hurd
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 27, 2026, 1:08 PM EDT
Completed Phase 2 Interventional

Study of Computer-Based Treatment for Drug Dependence

NCT01315184
View directory record Official record
Conditions
Opioid-Related Disorders, Heroin Dependence
Interventions
Recovery Line Support System
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 27, 2026, 1:08 PM EDT
Completed No phase listed Observational

Starting Treatment With Agonist Replacement Therapies Follow-up Study

NCT01592461
View directory record Official record
Conditions
Opioid Dependence
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 27, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

NCT01058642
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ADL5747, Placebo, Pregabalin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 27, 2026, 1:08 PM EDT